PharmaEssentia - Public Comps and Valuation Multiples

PharmaEssentia Overview

About PharmaEssentia

PharmaEssentia Corp is engaged in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug pattern developments. It focuses on Hematology, Oncology, and Infectious Diseases. The company derives its revenue from the sales of medicine products. Geographically, the company generates maximum revenue from America, followed by Europe, Asia (excluding Taiwan), and Taiwan.

Founded

2000

HQ

Employees

350

Website

pharmaessentia.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $348M

LTM EBITDA $79.1M

EV

$4.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

PharmaEssentia Financials

PharmaEssentia has a last 12-month revenue of $348M and a last 12-month EBITDA of $79.1M.

In the most recent fiscal year, PharmaEssentia achieved revenue of $294M and an EBITDA of $102M.

PharmaEssentia expects next 12-month revenue of XXX and NTM EBITDA of XXX

See PharmaEssentia valuation multiples based on analyst estimates

PharmaEssentia P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$154M	$294M	XXX	XXX	XXX
Gross Profit	$62.5M	$136M	XXX	XXX	XXX
Gross Margin	41%	46%	XXX	XXX	XXX
EBITDA	-$20.3M	$102M	XXX	XXX	XXX
EBITDA Margin	-13%	35%	XXX	XXX	XXX
Net Profit	-$41.5M	-$18.8M	XXX	XXX	XXX
Net Margin	-27%	-6%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

PharmaEssentia Stock Performance

As of April 23, 2025, PharmaEssentia's stock price is TWD 483 (or $15).

PharmaEssentia has current market cap of TWD 156B (or $4.7B), and EV of TWD 136B (or $4.1B).

See PharmaEssentia trading valuation data

PharmaEssentia Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$4.1B	$4.7B	XXX	XXX	XXX	XXX	$0.33

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

PharmaEssentia Valuation Multiples

As of April 23, 2025, PharmaEssentia has market cap of $4.7B and EV of $4.1B.

PharmaEssentia's trades at 11.8x LTM EV/Revenue multiple, and 51.9x LTM EBITDA.

Analysts estimate PharmaEssentia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for PharmaEssentia and 10K+ public comps

PharmaEssentia Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$4.1B	XXX	XXX	XXX
EV/Revenue	14.0x	XXX	XXX	XXX
EV/EBITDA	40.2x	XXX	XXX	XXX
P/E	52.7x	XXX	XXX	XXX
P/E/Growth	0.7x	XXX	XXX	XXX
EV/FCF	82.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PharmaEssentia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

PharmaEssentia Valuation Multiples

PharmaEssentia's NTM/LTM revenue growth is 53%

PharmaEssentia's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.6M for the same period.

Over next 12 months, PharmaEssentia's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate PharmaEssentia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for PharmaEssentia and other 10K+ public comps

PharmaEssentia Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	91%	XXX	XXX	XXX	XXX
EBITDA Margin	35%	XXX	XXX	XXX	XXX
EBITDA Growth	-604%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	88%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.8M	XXX	XXX	XXX	XXX
Opex per Employee	$0.6M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	25%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	19%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	27%	XXX	XXX	XXX	XXX
Opex to Revenue	70%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Streaming Platforms

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Explore Valuation Multiples by Industry